Diets · Metabolic & Cardiometabolic
time-restricted eating improves glycemic control
In plain terms: Does a daily eating window improve diabetic blood sugar?
Leans support Diets 🔬 Includes disconfirming
Part of: 🥗 time-restricted eating
RefutedContestedStrong support
consensus score 0.26
Yes, but the benefit is small and doesn't clearly beat simply matching calories.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
10 support 3 contradict 0 tested null 3 mixed · 16 sources, 13 independent groups · 3 superseded — pooled inside a review, counted once
What the evidence shows
TRE modestly improves glycemia (HbA1c ~-0.43%) and BP in type 2 diabetes - real but clinically small, with no clear superiority over calorie-matched comparators.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mohammadpour S, Hadaegh F, Zayeri F, Hosseinpour-Niazi S, Badrooj N, Shab-Bidar S, Mirmiran P 2026 · Diabetology & metabolic syndrome | RCT | mixed | low | 24-week RCT in 120 T2D adults: both calorie-carb restriction alone (CCR) and CCR+8h TRE (IFCCR) improved outcomes with adjustment for HbA1c change, but the trial's primary endpoints were eating-disorder psychopathology/distress, not HbA1c i |
| Andriessen C, Fealy CE, Veelen A, van Beek SMM, Roumans KHM, Connell NJ, Mevenkamp J, Moonen-Kornips E, Havekes B, Schrauwen-Hinderling VB, Hoeks J, Schrauwen P 2022 · Diabetologia | RCT | supports | moderate | Three weeks of TRE improved 24h glucose and time-in-range in free-living T2DM adults, though without changes in insulin sensitivity or hepatic glycogen ↩ SUPERSEDED — pooled in the review above, counted once |
| Chen J, Liu P, Wang M, Yan X, Li J, Guo J 2026 · Asia Pacific journal of clinical nutrition | meta-analysis | supports | moderate | Meta-analysis of 14 RCTs (899 T2D/prediabetes patients): intermittent fasting (including TRE protocols) reduced HbA1c more than ad libitum eating (SMD -0.64), with effects on HbA1c similar to continuous energy restriction (CERD). |
| Doraisamy BV, Argaistieng J, Masrudin SS, Zahli NIU, Ali AA, Maniam S 2026 · Nutr Rev | meta-analysis | supports | moderate | SR of human+rodent TRF: consistent improvements in glycemic control including HbA1c in T2DM |
| Sharma SK, Mudgal SK, Kalra S, Gaur R, Thakur K, Agarwal R 2023 · touchREV Endocrinol | meta-analysis | contradicts | moderate | SR/MA of 11 RCTs (13 arms) in T2DM, PROSPERO CRD42022328528: NO difference in HbA1c between intermittent fasting and control (SMD -0.08, 95% CI -0.20 to 0.04; p=0.19; I2=22%), and none in fasting glucose (7 studies; SMD 0.06, 95% CI -0.25 to 0.38; p=0.69; I2=76%); authors conclude 'IF and usual diet pattern have no difference in terms of glycaemic control'. Null in both duration strata (<=12wk SMD -0.03, p=0.38; >12wk SMD -0.31, p=0.14); the only significant signal is an age subgroup (9 studies, <=60y: SMD -0.20, 95% CI -0.39 to -0.01, p=0.04). Exposure is the IF umbrella, only 1 of 11 studies (2 of 13 arms) was time-restricted feeding; 9 of 13 arms compared IF against calorie-matched continuous energy restriction, not usual diet. |
| Molani-Gol R, Safari S, Esmaeil Zadeh Tolouei S, Rafraf M 2026 · Nutr Res | meta-analysis | supports | moderate | Umbrella review pooling 9 meta-analyses (not primary trials): 'Nine meta-analyses comprising 15 randomized controlled trials of 6386 participants with T2DM were included'; TRE reduced 'glycated hemoglobin (WMD = -0.428, 95% CI [-0.682, -0.173])' and 'fasting blood sugar (WMD = -7.514 mg/dL, 95% confidence interval [CI] [-10.959, -4.068])'. Units are syntheses already counted in the vault, so review role (zero weight). |
| Afif CP, Brewster KP, Zhang MP, Reeves J, Hackbarth MT, Cong C, Olvera K, Moya EA, Malhotra A, Mesarwi OA 2026 · Sleep | animal | supports | moderate | Mouse model of OSA-associated dysglycemia: 9h/day TRE reduced fasting glucose and prevented glucose-tolerance-test AUC increases seen with ad-lib feeding; effect linked to improved pancreatic insulin secretion, not reported as HbA1c. |
| Obermayer A, Tripolt NJ, Pferschy PN, Kojzar H, Aziz F, Müller A, Schauer M, Oulhaj A, Aberer F, Sourij C, Habisch H, Madl T, Pieber T, Obermayer-Pietsch B, Stadlbauer V, Sourij H 2022 · Diabetes Care | RCT | supports | moderate | Intermittent fasting safely ameliorated glycemic control while reducing total daily insulin dose and body weight in insulin-treated T2DM |
| Rovira-Llopis S, Luna-Marco C, Perea-Galera L, Bañuls C, Morillas C, Victor VM 2023 · Rev Endocr Metab Disord | meta-analysis | mixed | high | SR: timing matters; only early-TRE reduced fasting glucose in overweight/obese, suggesting HbA1c benefit is conditional on circadian alignment |
| Guo L, Xi Y, Jin W, Yuan H, Qin G, Chen S, Zhang L, Liu Y, Cheng X, Liu W, Yu D 2024 · JAMA Netw Open | RCT | supports | moderate | 5:2 intermittent-fasting meal-replacement diet lowered HbA1c more than metformin or empagliflozin short-term in early T2DM |
| Nam T, Oh H, Kim A, Oh Y 2025 · Int J Mol Sci | meta-analysis | supports | moderate | [FT-verified] FT 8-RCT HbA1c MD only -0.11%; real but clinically small |
| Parr EB, Radford BE, Hall RC, Steventon-Lorenzen N, Flint SA, Siviour Z, Plessas C, Halson SL, Brennan L, Kouw IWK, Johnston RD, Devlin BL, Hawley JA 2024 · Diabetes Res Clin Pract | RCT | supports | moderate | TRE improved glycaemic control in people with T2DM and is proposed as an alternative when individualised dietary guidance is unavailable |
| Khalafi M, Habibi Maleki A, Symonds ME, Rosenkranz SK, Rohani H, Ehsanifar M 2024 · Diabetes Obes Metab | meta-analysis | contradicts | high | SR/MA: intermittent fasting reduced body weight/BMI vs continuous restriction but had NO effect on glycaemic markers, lipids or blood pressure |
| Kramer CK, Zinman B, Feig DS, Retnakaran R 2025 · J Clin Endocrinol Metab | RCT | supports | moderate | TRE improved beta-cell function and insulin resistance in overweight early-diabetes patients with beneficial adiposity changes ↩ SUPERSEDED — pooled in the review above, counted once |
| Laing KL, Levy JL, Wilkinson MJ, Varshney S, Panda S, Taub PR, Manoogian ENC 2026 · Frontiers in clinical diabetes and healthcare | observational | supports | low | 3-patient case series of T2DM adults on stable GLP-1RA following 8-10h TRE for 3 months: all 3 had HbA1c and nighttime glucose reductions plus improved time-in-range. |
| Yang X, Zhou J, Shao H, Huang B, Kang X, Wu R, Bian F, Hu M, Liu D 2023 · J Clin Endocrinol Metab | RCT | supports | moderate | Intermittent calorie-restricted CMNT diet achieved durable diabetes remission for at least 1yr with marked HbA1c reduction vs control |
| Kloura C, Jensen MM, Ekblond TS, Pedersen HE, Raben A, Clemmensen KKB, Færch K, Blond MB, Quist JS 2026 · Diabetes research and clinical practice | RCT | contradicts | moderate | RESET trial secondary analysis in 46 adults with prediabetes: no between-group difference in HbA1c or fasting glucose at 6 weeks or 3 months for 10-h TRE vs control; only a small transient nighttime-glucose benefit. |
| Lu X, You J, Xia T, Xu R 2026 · Diabetol Metab Syndr | meta-analysis | supports | moderate | TRE MA (12 studies, 344 T2D): HbA1c -0.32%, FBG -0.44 mmol/L, improved time-in-range |
| Liu F, Zhang Z, Sun W, Li T 2025 · Nutr Res | meta-analysis | mixed | moderate | IF effectively manages blood sugar and weight in T2DM but metabolic/HbA1c benefits do NOT endure after discontinuation |
| Pavlou V, Cienfuegos S, Lin S, Ezpeleta M, Ready K, Corapi S, Wu J, Lopez J, Gabel K, Tussing-Humphreys L, Oddo VM, Alexandria SJ, Sanchez J, Unterman T, Chow LS, Vidmar AP, Varady KA 2023 · JAMA Netw Open | RCT | supports | moderate | FT JAMA n=75 TRE HbA1c -0.91% but identical to CR -0.94%; benefit via energy reduction not TRE-specific ↩ SUPERSEDED — pooled in the review above, counted once |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.